Otilimab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A fully human monoclonal antibody directed against the inflammatory mediator granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immunomodulating activity. Upon administration, otilimab targets, binds to and neutralizes GM-CSF. This prevents the binding of GM-CSF to its targeted inflammatory cells, and prevents proliferation and activation of various immune cells, and subsequent release of cytokines and B- and T-cell responses. GM-CSF, a monomeric glycoprotein functioning as a cytokine promoting both proliferation and activation of macrophages and neutrophils. GM-CSF levels are elevated in certain immune-mediated diseases. It increases the production of pro-inflammatory mediators, such as cytokines, chemokines and proteases.

**Synonyms:** - GSK3196165 - Immunoglobulin G1, Anti-(Human Granulocyte-Macrophage Colony-stimulating Factor) (Human Monoclonal GSK3196165 Heavy Chain), Disulfide with Human Monoclonal GSK3196165 Lambda-chain, Dimer - MOR103 - OTILIMAB